OTC · CIK 0001938571
APTN ADAPTIN BIO, INC.
Insider trading from SEC Form 4. Last filing Sep 10, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
7
with a Form 4 at this company
Signals
Open-market buys and sells at ADAPTIN BIO, INC., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 7 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 8, 2025 | L Arthur Hewitt Chief Development Officer | AGrant or award Stock Option (right to buy)derivative | +109,847 | $0.00 | $0 | 109,847 | Sep 10, 2025 |
| Sep 8, 2025 | Timothy Maness Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +192,231 | $0.00 | $0 | 192,231 | Sep 10, 2025 |
| Sep 8, 2025 | Patrick Joseph Gallagher director | AGrant or award Stock Option (right to buy)derivative | +109,847 | $0.00 | $0 | 109,847 | Sep 10, 2025 |
| Sep 8, 2025 | J Nick Riehle director | AGrant or award Stock Option (right to buy)derivative | +109,847 | $0.00 | $0 | 109,847 | Sep 10, 2025 |
| Sep 8, 2025 | Anthony P. Zook director | AGrant or award Stock Option (right to buy)derivative | +109,847 | $0.00 | $0 | 109,847 | Sep 10, 2025 |
| Sep 8, 2025 | Simon Pedder Executive Chairman | AGrant or award Stock Option (right to buy)derivative | +192,231 | $0.00 | $0 | 192,231 | Sep 10, 2025 |
| Sep 8, 2025 | Michael J Roberts President and CEO | AGrant or award Stock Option (right to buy)derivative | +439,386 | $0.00 | $0 | 439,386 | Sep 10, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Patrick Joseph Gallagherdirector
- L Arthur HewittChief Development Officer
- Timothy ManessChief Financial Officer
- Simon PedderExecutive Chairman
- J Nick Riehledirector
- Michael J RobertsPresident and CEO
- Anthony P. Zookceo, officer, director
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.